Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
ico-007 (1 trial)
ranibizumab (lucentis) (1 trial)
squalamine (1 trial)
Diabetic Retinopathy (Phase 2)
Edema (Phase 2)
Macular Edema (Phase 2)
Neovascularization, Pathologic (Phase 2)
Retinal Diseases (Phase 2)
Retinal Neovascularization (Phase 2)
Trials (2 total)
Trial APIs (3 total)